Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
V
310210
vs
K
KOSPI 200
Over the past 12 months, Voronoi Inc has underperformed KOSPI 200, delivering a return of -46% compared to KOSPI 200's +50% growth.
Stocks Performance
310210 vs KOSPI 200
Performance Gap
310210 vs KOSPI 200
Performance By Year
310210 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Voronoi Inc
Glance View
Voronoi Inc is a South Korean biopharmaceutical company that discovers and develops small-molecule cancer drugs. It focuses on finding drug candidates that can block the signaling pathways cancer cells use to grow and survive, then advancing those candidates through preclinical and clinical development. The company’s main customers are not patients directly but pharmaceutical partners, healthcare systems, and eventually doctors and hospitals if its drugs win approval. Voronoi makes money mainly by developing its own drug pipeline and by partnering with larger drug companies that can help fund, license, or commercialize those programs. In this model, most of the value comes from turning early scientific research into patent-protected therapies that can be sold as prescription medicines. That means its business depends on scientific success, regulatory approval, and the ability to prove a drug is safe and effective. What sets Voronoi apart is that it sits at the risky, research-heavy front end of the drug value chain rather than selling finished medicines today. It is a creator of drug candidates, not a broad pharmaceutical manufacturer. For beginner investors, the key idea is simple: Voronoi is building a pipeline of cancer treatments that could become licensed products or sold drugs if development succeeds.